MRTX Mirati Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MRTX

Price (delayed)

$161.72

Market cap

$8.19B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.96

Enterprise value

$7.34B

Sector: Healthcare
Industry: Biotechnology
Website: https://www.mirati.com/

Highlights

MRTX's equity has soared by 147% from the previous quarter
The quick ratio has soared by 129% year-on-year and by 126% since the previous quarter
Mirati Therapeutics's net income has shrunk by 68% YoY and by 9% QoQ
The EPS fell by 40% YoY and by 3% QoQ

Key stats

What are the main financial stats of MRTX
Market
Shares outstanding
50.63M
Market cap
$8.19B
Enterprise value
$7.34B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.98
Price to sales (P/S)
543.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
548.21
Earnings
Revenue
$13.4M
EBIT
-$357.94M
EBITDA
-$357.3M
Free cash flow
-$275.9M
Per share
EPS
-$7.96
Free cash flow per share
-$6.13
Book value per share
$27.06
Revenue per share
$0.3
TBVPS
$32.81
Balance sheet
Total assets
$1.48B
Total liabilities
$115.34M
Debt
$41.91M
Equity
$1.36B
Working capital
$1.33B
Liquidity
Debt to equity
0.03
Current ratio
19.64
Quick ratio
19.45
Net debt/EBITDA
2.36
Margins
EBITDA margin
-2,666.8%
Gross margin
100%
Net margin
-2,671.6%
Operating margin
-2,756.9%
Efficiency
Return on assets
-41.2%
Return on equity
-45.1%
Return on invested capital
-75%
Return on capital employed
-25.5%
Return on sales
-2,671.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRTX stock price

How has the Mirati Therapeutics stock price performed over time
Intraday
0.55%
1 week
2.23%
1 month
-8.94%
1 year
90.78%
YTD
-26.37%
QTD
-5.59%

Financial performance

How have Mirati Therapeutics's revenue and profit performed over time
Revenue
$13.4M
Gross profit
$13.4M
Operating income
-$369.36M
Net income
-$357.94M
Gross margin
100%
Net margin
-2,671.6%
Mirati Therapeutics's net income has shrunk by 68% YoY and by 9% QoQ
The company's operating income has shrunk by 66% YoY and by 9% QoQ
The operating margin has soared by 59% YoY
Mirati Therapeutics's net margin has soared by 58% YoY

Growth

What is Mirati Therapeutics's growth rate over time

Valuation

What is Mirati Therapeutics stock price valuation
P/E
N/A
P/B
5.98
P/S
543.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
548.21
The EPS fell by 40% YoY and by 3% QoQ
MRTX's equity has soared by 147% from the previous quarter
MRTX's price to book (P/B) is 32% lower than its last 4 quarters average of 8.7
The price to sales (P/S) is 61% lower than the last 4 quarters average of 1387.8
MRTX's revenue is up by 10% since the previous quarter

Efficiency

How efficient is Mirati Therapeutics business performance
The ROS has soared by 58% YoY
The company's return on equity rose by 25% QoQ and by 17% YoY
Mirati Therapeutics's return on assets has increased by 24% QoQ and by 17% YoY
MRTX's return on invested capital is up by 4% since the previous quarter and by 2.3% year-on-year

Dividends

What is MRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRTX.

Financial health

How did Mirati Therapeutics financials performed over time
The total assets has soared by 138% from the previous quarter
The total liabilities has soared by 131% YoY and by 67% QoQ
Mirati Therapeutics's debt is 97% less than its equity
MRTX's equity has soared by 147% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.